Rep. Richard McCormick Acquires Abbott Laboratories (NYSE:ABT) Shares

Posted by Casey Walker on Jul 18th, 2026

Representative Richard McCormick (Republican-Georgia) recently bought shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on July 09th, the Representative disclosed that they had bought between $1,001 and $15,000 in Abbott Laboratories stock on June 12th. The trade occurred in the Representative’s “GROWTH PARTNERS IRA” account.

Representative Richard McCormick also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Analog Devices (NASDAQ:ADI) on 6/12/2026.
Sold $1,001 – $15,000 in shares of BlackRock (NYSE:BLK) on 6/12/2026.
Sold $1,001 – $15,000 in shares of Cisco Systems (NASDAQ:CSCO) on 6/12/2026.
Purchased $1,001 – $15,000 in shares of Intercontinental Exchange (NYSE:ICE) on 6/12/2026.
Purchased $1,001 – $15,000 in shares of L3Harris Technologies (NYSE:LHX) on 6/12/2026.
Sold $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 6/12/2026.
Sold $1,001 – $15,000 in shares of American Tower (NYSE:AMT) on 4/17/2026.

Abbott Laboratories Price Performance

ABT stock traded up $1.88 during trading on Friday, hitting $100.71. 19,913,032 shares of the stock traded hands, compared to its average volume of 11,962,257. The stock has a market cap of $175.41 billion, a price-to-earnings ratio of 32.59, a P/E/G ratio of 1.70 and a beta of 0.61. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The company has a 50 day simple moving average of $89.89 and a 200 day simple moving average of $102.17.

Abbott Laboratories (NYSE:ABT – Get Free Report) last posted its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. The company had revenue of $12.51 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The company’s revenue was up 13.0% on a year-over-year basis. During the same quarter last year, the business posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities analysts expect that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Wednesday, July 15th. Abbott Laboratories’s payout ratio is currently 70.59%.

Insiders Place Their Bets

In other Abbott Laboratories news, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were acquired at an average cost of $92.65 per share, with a total value of $926,500.00. Following the acquisition, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Philip P. Boudreau purchased 2,200 shares of the business’s stock in a transaction on Thursday, April 23rd. The shares were acquired at an average cost of $91.50 per share, with a total value of $201,300.00. Following the acquisition, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 0.46% of the company’s stock.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: Abbott beat Q2 earnings expectations and raised 2026 adjusted EPS guidance to $5.45-$5.60, signaling better profit momentum for the rest of the year. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
Positive Sentiment: Management pointed to stronger second-half demand across multiple businesses, including nutrition, medical devices, diagnostics, and diabetes care, which supports a faster growth profile. ABT Q2 Earnings Call Flags Stronger Second-Half Setup
Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan, Citi, Piper Sandler, Wells Fargo, TD Cowen, BTIG, and RBC all lifting targets or reaffirming bullish views. These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

Hedge Funds Weigh In On Abbott Laboratories

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Freemont Management S.A. grew its stake in Abbott Laboratories by 197.2% in the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock valued at $1,341,000 after purchasing an additional 7,100 shares in the last quarter. PFA Pension Forsikringsaktieselskab bought a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $116,580,000. Thrivent Financial for Lutherans boosted its holdings in shares of Abbott Laboratories by 24.3% in the 4th quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock valued at $30,931,000 after buying an additional 48,286 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab bought a new position in shares of Abbott Laboratories in the third quarter valued at $185,640,000. Finally, Net Worth Advisory Group acquired a new position in Abbott Laboratories during the fourth quarter worth $1,366,000. Institutional investors own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on ABT shares. Barclays dropped their target price on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research report on Monday, April 20th. Robert W. Baird initiated coverage on Abbott Laboratories in a research report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price objective for the company. Mizuho cut their target price on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a research report on Friday, April 17th. TD Cowen reaffirmed a “buy” rating and issued a $115.00 target price on shares of Abbott Laboratories in a research note on Friday. Finally, Daiwa Securities Group downgraded shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target for the company. in a research note on Wednesday, April 22nd. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $118.61.

Check Out Our Latest Stock Analysis on Abbott Laboratories

About Representative McCormick

Rich McCormick (Republican Party) is a member of the U.S. House, representing Georgia’s 7th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

McCormick (Republican Party) is running for re-election to the U.S. House to represent Georgia’s 7th Congressional District. He declared candidacy for the 2026 election.

Rich McCormick lives in Suwanee, Georgia. McCormick served in the U.S. Marine Corps and the U.S. Navy. He earned an M.B.A. from National University and an M.D. from Morehouse School of Medicine. McCormick’s career experience includes working as an emergency medicine physician with Gwinnett Medical Center and Northside Hospital, a Marine officer instructor with Georgia Tech and Morehouse College, and a pilot.

About Abbott Laboratories

(Get Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.